Benefits of β-blockers in cancer treatment
Tyagita N., Safitri A.H., Arif M., Hardianti M.S.
Abstract
Cancer is one of the leading causes of death in the world. Researchers keep attempting to develop therapy modalities to decrease the mortality and morbidity of cancer patients by trying to comprehend the effect of sympathetic nerves (through catecholamine and adrenergic receptors) in cancer development. Catecholamine activation in β-adrenergic receptors (β1-AR, β2-AR, and β3-AR) may influence cytokine and cancer immunity system, initiate tumorigenesis, stimulate tumor-associated macrophage and angiogenesis, influence tumor microenvironment, and facilitate cancer cell metastasis, leading to increased progressivity of cancer cells. β-blockers may inhibit catecholamine on β-AR and various types of paths needed for cancer cells to develop. β-blockers also stimulate cancer cell apoptosis, decrease pro-inflammatory mediators and growth factors of cancer cells. In addition, β-blockers also have benefits as supplementary cancer therapy, increase chemoradiotherapy sensitivity, decrease cardiotoxicity, and improve cancer cachexia. The benefits of β-blockers are expected to reduce morbidity and increase the survival rates of cancer patients. This review comprehensively assesses the benefit of β-blockers as a part of the complete management of cancer patients.
Beta blockers and cancer prognosis - The role of immortal time bias: A systematic review and meta-analysis
Brenner H., Carr P.R., Hoffmeister M., Jansen L., Weberpals J.
Epidemiology, incidence and mortality of lung cancer and their relationship with the development index in the world
Hesami S.M., Khani F., Makhsosi B.R., Mehtarpour M., Moini A., Rafiemanesh H., Salehiniya H., Salehiniya H., Shamlou R., Towhidi F.
An Overview of Molecular Cancer Pathogenesis, Prognosis, and Diagnosis
Breen M., Cullen J
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Akbani R., Armenia J., Bahceci I., Bailey M.H., Berger A.H., Bernard B., Bivona T.G., Broom B.M., Caesar-Johnson S.J., Chakravarty D., Chambwe N., Chatila W.K., Chatila W.K., Cho J., Chudamani S., Daian F., DeFreitas T., Demchok J.A., Dervishi L., Dhankani V., Dimitriadoy S., Ding L., Ding L., Dogrusoz U., Felau I., Ferguson M.L., Foltz S.M., Frazer S., Frederick M.J., Gao J., Gao J., Gao Q., Gehlenborg N., Getz G., Giordano T., Giordano T., Giordano T., Giordano T., Greene C.S., Gross B., Hammer G.D., Hegde A.M., Heiman D.I., Heins Z., Huang C., Hutter C.M., Iavarone A., Ju Z., Kanchi R.S., Kandoth C., Kantheti H.S., Kasapi M., Kim J., Knijnenburg T., Kramer R., Kundra R., Kwong L.N., La K.C., Laird P.W., Lawrence M.S., Lazar A.J., Lazar A.J., Leinonen K., Liang H., Liang W.-W., Lin P., Liu D.L., Liu D.L., Liu J., Liu Y., Lolla L., Luna A., Luna A., McArthur G., McArthur G., McCormick F., Meier S., Meyerson M., Meyerson M., Miller M., Mina M., Naresh R., Noble M.S., Ochoa A., Pihl T., Reynolds S., Saghafinia S., Saksena G., Sanchez-Vega F., Sanchez-Vega F., Shen H., Shmulevich I., Shmulevich I., Sofia H.J., Sun Q., Tarnuzzer R., Thorsson V., Tward A.D., Voet D., Wan Y., Wang C., Wang Z., Way G.P., Wu Y., Xiao Y., Yang L., Zenklusen J.C., Zhang H., Zhang H., Zhang J.J., Zhang W., Zhou W.
Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies
Dubowitz J., Dubowitz J., Gottumukkala V., Hiller J., Hiller J., Hiller J., Lopez-Olivo M.A., Pratt G., Riedel B., Riedel B., Riedel B., Schier R., Schier R., Sloan E., Sloan E., Sloan E., Yap A., Yap A.
Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival.
Ellis I.O., Entschladen F., Green A.R., Habashy H.O., Powe D.G., Voss M.J., Zanker K.S.
The effects of beta-blocker use on cancer prognosis: A meta-analysis based on 319,006 patients
Fan L., Feng Z., Guo W., Hao X., Li D., Li J., Li J., Na Z., Qiao X., Shao Y., Sun M., Xiao Y.
Meta-analysis of the effects of beta blocker on survival time in cancer patients
Bae D.-S., Choi C.H., Choi J.K., Kim B.-G., Kim T.-J., Kim T.H., Lee J.-W., Lee Y.-Y., Park J.-Y., Song T., Yoon A.
β-blocker use and mortality in cancer patients: Systematic review and meta-analysis of observational studies
Chen X., Tang J., Wang S., Yang S., Yu D., Zhang X., Zhao J., Zhong S.
Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial)
Anker S.D., Beadle J., Brown R., Ho G.F., Prabhash K., Stewart Coats A.J., Stewart Coats A.J., Tilson J., von Haehling S.
Zhou X., Yang Q., Sia C.-H., Sun P., A G., Li L., Liu H., Guo Y., Li J., Zuo L., Jiang S.
American Journal of Medicine
Maden-Wilkinson T., Humphreys L.J., Myers A., Welfare S., Dalton C., Copeland R.
BMJ Open
Journal of Translational Medicine
Awuah W.A., Awuah W.A., Roy S., Shah M.H., Bharadwaj H.R., Gaur A., Guernaoui A.E., Imran S., Rao M.S., Roy S.
Current Problems in Cardiology
Ismail A.F.M., Nagy A.A., Osman A.H., Tamim Y.M., Abdellah A.M.
Fundamental and Clinical Pharmacology
Gandhi S., Puzanov I., Switzer B., Repasky E.A.
Melanoma Research
Galli S., Sejda A., Sigorski D., Gulczynski J., Kitlinska J., Rogowski W., Izycka-Swieszewska E.
Biomedicines
